Skip to main content

Table 1 Time to treatment initiation (TTI) Evaluations

From: Time abides long enough for those who make use of it

  Data Source Years n Site Median TTI HRa
Fortin A [25] Retrospective single institution 1988–1997 623 T1-2 N0 HNC 1989: 28 d 1.45 (1.06–1.97)
55% Larynx 1995: 46 d Delay > 30 d
  1997: 55 d
Leon X [23] Retrospective single institution 1985–1998 797 All HNC 44 d 0.99 (0.83–1.19)
45% Larynx Delay > 33 d
Hansen O [13] Retrospective single institution 1965–1997 611 Stage I-III 21 d 1.16 (0.84–1.59)
Glottic Cancer Continuous
Caudell J [24] Retrospective single institution 1995–2007 427 Stage III-IV HNC 34 d 1.002 (0.999–1.005)
55% Oropharynx Continuous
Liang H [22] Retrospective single institution 1998–2013 9896 Stage I-IV NPC RT: 20 d 1.13 (1.04–1.23)
45% Stage III CRT: 22 d Delay > 30 d
Murphy CT [26] Prospective Database 2003–2006 51,655 All HNC 26 d 1.08 (1.03–1.13)
42% Larynx Delay 61–90 d
  1. HNC = head and neck cancer, RT = RT alone, CRT = chemoradiation, d = days
  2. aHR is a comparison of survival as a function of increased TTI. Comparison is TTI ≤ 30 days v the interval specified or an evaluation of increased TTI as a continuous variable